Shares of Myokardia Inc (NASDAQ:MYOK) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $79.14.
Several research analysts have issued reports on MYOK shares. Zacks Investment Research upgraded shares of Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Tuesday. JPMorgan Chase & Co. set a $90.00 price target on shares of Duke Energy and gave the company a “hold” rating in a report on Monday, May 20th. ValuEngine cut shares of Zogenix from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Morgan Stanley set a $70.00 price target on shares of Edison International and gave the company a “hold” rating in a report on Monday. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th.
In other news, insider Anastasios Gianakakos sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $49.73, for a total value of $198,920.00. Following the sale, the insider now directly owns 116,470 shares in the company, valued at approximately $5,792,053.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. GAM Holding AG acquired a new stake in Myokardia in the 1st quarter worth approximately $2,128,000. Great West Life Assurance Co. Can raised its position in Myokardia by 27.8% during the 4th quarter. Great West Life Assurance Co. Can now owns 4,188 shares of the biotechnology company’s stock worth $197,000 after buying an additional 912 shares during the last quarter. Hillhouse Capital Advisors Ltd. purchased a new position in Myokardia during the 4th quarter worth approximately $41,938,000. DekaBank Deutsche Girozentrale raised its position in Myokardia by 22.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 12,600 shares of the biotechnology company’s stock worth $753,000 after buying an additional 2,350 shares during the last quarter. Finally, Samlyn Capital LLC raised its position in Myokardia by 180.5% during the 4th quarter. Samlyn Capital LLC now owns 283,908 shares of the biotechnology company’s stock worth $13,872,000 after buying an additional 182,681 shares during the last quarter. Institutional investors own 99.64% of the company’s stock.
Myokardia stock traded up $1.31 during midday trading on Friday, hitting $51.13. 1,829 shares of the company’s stock were exchanged, compared to its average volume of 328,594. Myokardia has a 12 month low of $39.01 and a 12 month high of $67.79. The business’s 50-day moving average price is $48.28. The firm has a market cap of $2.34 billion, a P/E ratio of -29.16 and a beta of 2.06.
Myokardia (NASDAQ:MYOK) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.28). Myokardia had a negative return on equity of 19.98% and a negative net margin of 201.81%. Sell-side analysts predict that Myokardia will post -3.75 earnings per share for the current year.
Myokardia Company Profile
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Read More: Analyst Ratings Trading
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.